Exercise training's impact on quality of life in lung disease patients
The Effect of Exercise Training on Quality of Life and Disease Progression in Fibrosing Interstitial Lung Patients
This study is testing if a special exercise program can improve the quality of life for people with fibrosing interstitial lung disease over a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 56 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Istanbul Medipol University Hospital Academic / other |
| Locations | 1 site (Istanbul, Üsküdar) |
| Trial ID | NCT06527612 on ClinicalTrials.gov |
What this trial studies
This study examines the effects of a pulmonary rehabilitation exercise program on patients with fibrosing interstitial lung disease over a one-year follow-up period. Patients will be randomized into two groups: one receiving the exercise program and the other serving as a control group. The exercise group will participate in initial hospital-based training followed by home exercises monitored through video conferencing and weekly surveys. The study aims to assess changes in disease progression and quality of life at 3, 6, and 12 months.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 diagnosed with fibrosing interstitial lung disease who experience dyspnea on exertion and are clinically stable.
Not a fit: Patients with severe comorbidities, unstable coronary artery disease, or those who cannot participate in exercise training will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the quality of life and slow disease progression for patients with fibrosing interstitial lung disease.
How similar studies have performed: Other studies have shown positive outcomes with pulmonary rehabilitation in similar patient populations, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged between 18-75 years * Diagnosed with fibrosing interstitial lung disease according to the clinical diagnostic criteria of the American Thoracic Society and European Respiratory Society (ATS-ERS) * Presence of dyspnea on exertion * Stable clinical condition at the time of inclusion without infection or exacerbation in the previous 4 weeks * Proficiency in using a smartphone Exclusion Criteria: * Severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases, or requiring high-flow oxygen therapy (\> 3-4 L/min) * History of exertional syncope or any comorbidity that prevents exercise training (such as severe orthopedic or neurological deficits or unstable heart disease) * Participation in a pulmonary rehabilitation program within the last 12 months
Where this trial is running
Istanbul, Üsküdar
- Esra Pehli̇van — Istanbul, Üsküdar, Turkey (Türkiye) (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.